甘精胰岛素_NPH胰岛素联合口服降糖药在2型糖尿病患者中的应用.pdfVIP

262 2006 27 4 NPH 2 陈 超 莫尉林 邢学农 李素梅 叶山东 任 安 [ ] 2 , NPH HbAlc 7% 33 2 2 ( HbAlc 7. 5%) , 16 , , NPH , ( FBG) 100 mg/ dl ( 5. 6 mmol/ ) FBG HbAlcHbAlc 7% NPH FBG( 5. 94Vs6. 11 mol/ ) HbAlc(6. 68Vs6.79%) ,P 0. 05 HbAlc 7% , HbAlc 7% ( 4 mmol/ ) , ( 69%) NPH ( 29%) , P 0. 05 NPH ,P 0.05 2 , , (HbAlc 7%) NPH [] ; NPH ; HbAlc; Oral therapy combined with bedtimeinsulin glargine orbedtimeNPH insulininpatients with type2 diabetes Chen Chao , Mo We ilin, X ing X uenong , et al Dep ar tment of E ndocr ine, A nh ui P r ov incial H osp ital H ef e i 230001 [Abstract] Objective To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral therapy of type 2 diabetes to achive HbAlc less t han 7% . Methods In a randomized, openla bel, parallel, 16week trial, 33 patients w ith inadequate glycemic control ( HbAlc 7.5%) on one or two oral agents con tinued prestudy oral agents and received bedtime glargine or NPH once daily, in order to seek a target fast ing plasma glu cose ( FPG) 5. 6mmol/ l. Outcome measures w ere FPG, HbAlc, hypoglycemia, and percentage of patients reaching HbAlc 7% without documented nocturnal hypoglycemina.Results M ean FPG at end point was simlar w ith glargine and NPH ( 5. 94Vs6. 11mmol/ l) , as was HbAlc ( 6. 68Vs6. 79%) , P 0. 05. A majority of pat ients (above 70%) attained HbAlc 7%w it h each insulin type. How ever, above one times more patients attained this w ithout documented nocturnal hypoglycemia( 4. 0mmol/ l) w ith glargine ( 69vs29%)P 0.05. M oreover, rates of symptomat